AXGN Axogen, Inc.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a pro…
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.The strategic acquisition integrates NerveTape, the first FDA-approved sutureless nerve repair device, into Axogen’s existing surgical solutions for restoring peripheral nerve function.Funding The AcquisitionTo finance the $200 million purchase price, Axogen launched an underwritten public offering of 4.91 million shares of common stock, pri | ||
2 Medical-Device Stocks Lighting Up the Options Pits Both AXGN and COO are seeing unusual options volume | ||
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday Amid Producer Price Inflation Data Release The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6%, and the actively t | ||
 Axogen (AXGN) Q2 2026 Earnings Call Transcript Breast segment revenue surged over 50% year over year, driving accelerated growth. | ||
 Axogen (AXGN) Is Up 5.1% After Raising 2026 Outlook On Breast Reconstruction Surge - Has The Bull Case Changed? In the second quarter of 2026, Axogen reported sales of US$69.73 million, a net loss of US$1.52 million, and lifted its full-year 2026 revenue outlook to at least US$279 million, implying revenue growth of at least 24%. A key highlight was the rapid expansion of Axogen’s breast reconstruction franchise, which drove more than half of quarterly revenue and reshaped the company’s product mix and margin profile. We’ll now explore how Axogen’s upgraded 2026 revenue outlook and breast... | ||
Axogen Inc (AXGN) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Margin Challenges Axogen Inc (AXGN) reports a robust 23% revenue increase, driven by the breast market, while navigating margin pressures and strategic expansion. | ||
 AxoGen Q2 Earnings Call Highlights AxoGen (NASDAQ:AXGN) reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing gr | ||
 AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates AxoGen (AXGN) delivered earnings and revenue surprises of +33.33% and +4.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 NZS Capital Added Axogen (AXGN) as an Optionality Position NZS Capital, LLC, an investment management company, released its “NZS Growth Equity Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. Equity markets delivered a strong performance in the second quarter of 2026, driven by demand for AI infrastructure, geopolitical stabilization, and positive earnings reports. The portfolio achieved a gross […] | ||
Nvidia Returns to NZS Growth Fund NZS shifts capital toward AI infrastructure and healthcare leaders | ||